A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Roche

Status and phase: Completed; Phase 2

Conditions: HIV Infections

Treatments: Drug: Zidovudine; Drug: Saquinavir; Drug: Lamivudine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002190

229N

NV15114

Details and patient eligibility

About

To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.

Full description

A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

• HIV antibody positive.
• CD4 count >= 150 and <= 500 cells/mm3.

Exclusion Criteria

Prior Medication:

Excluded:

• Prior antiretroviral therapy.
• Prior protease inhibitor therapy.